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Whilst it is established that CMV disease affects NK-cell profiles, the functional 35 
consequences of asymptomatic CMV replication are unclear. Here we characterise NK cells 36 
in clinically stable renal transplant recipients (RTR; n=48) >2 years after transplantation. 37 
RTRs and age-matched controls (n=32) were stratified by their CMV serostatus and the 38 
presence of measurable CMV DNA. CMV antibody or CMV DNA influenced expression of 39 
NKG2C, LIR-1, NKp30, NKp46 and FcRγ, a signaling adaptor molecule, on CD56dim NK 40 
cells. Phenotypic changes ascribed to CMV were clearer in RTRs than in control subjects, 41 
and affected NK-cell function as assessed by TNF- and CD107a expression. The most 42 
active NK cells were FcRγ–LIR-1+NKG2C– and displayed high antibody-dependent cell 43 
cytotoxicity (ADCC) responses in the presence of immobilised CMV glycoprotein B reactive 44 
antibody. However, perforin levels in supernatants from RTRs with active CMV replication 45 
were low. Overall we demonstrate that CMV can be reactivated in symptom-free renal 46 
transplant recipients, affecting the phenotypic and functional profiles of NK-cells. 47 
Continuous exposure to CMV may maintain and expand NK cells that lack FcRγ but express 48 




















Natural Killer (NK) cells are large granular lymphocytes involved in control of virus-infected 68 
and tumour cells. Their function is regulated by diverse families of surface receptors with no 69 
gene rearrangement as the cells differentiate. NK cells are divided into two groups based on 70 
cell surface density of CD56 (cytokine-producing CD56bright and cytotoxic CD56dim cells). 71 
CD56dim NK cells are more mature, less proliferative and express inhibitory and activating 72 
receptors such as Killer Immunoglobulin-like receptors (KIR), C-type lectin-like receptors 73 
(e.g. CD94/NKG2C or NKG2A), leukocyte immunoglobulin receptors (e.g. LIR-1) and 74 
natural cytotoxicity receptors (NCRs) such as NKp30 and NKp46 [1, 2]. These receptors 75 
monitor changes in the expression of class I molecules on stressed cells to induce target cell 76 
lysis. Target cell lysis can also be initiated by CD16, a low-affinity Fc receptor on NK cells 77 
that initiates antibody dependent cellular cytotoxicity (ADCC) after it is cross-linked by an 78 
IgG antibody [2–4] 79 
 80 
Cytomegalovirus (CMV) is a herpes virus that persists without symptoms in an 81 
immunocompetent host, but can cause serious complications in immunosuppressed 82 
individuals such as renal transplant recipients (RTRs) [5]. NK cells can control CMV 83 
infection even in the absence of an effective T cell response [6]. Moreover, CMV has the 84 
unique ability to imprint on the NK-cell receptor repertoire by altering expression of both 85 
inhibitory and activating receptors [7,8]. CMV also encodes proteins able to subvert NK-cell 86 
recognition of target cells. For example, LIR-1 binds with much higher affinity to CMV 87 
UL18 than to its natural ligand HLA-G [9]. CMV-infected cells expressing UL18 inhibited 88 
LIR-1+ NK cells, whereas LIR-1– NK cells were activated in the presence of CMV UL18 89 
[10]. Increased expression of LIR-1 on NK cells has been observed in CMV-seropositive 90 
individuals [7,11], but the function of these cells is unclear. CMV also encodes UL40 that up-91 
regulates cell surface expression of HLA-E. NKG2C can recognize HLA-E carrying an 92 
appropriate peptide, but HLA-E binds with much higher affinity to NKG2A (an inhibitory 93 
receptor) to inhibit NK cell mediated lysis [9]. 94 
 95 
CMV promotes the accumulation of NKG2C+ NK cells in healthy individuals [7,12,13]. In 96 
recipients of solid organ and haematopoietic stem cell transplants, NKG2C+ NK cells expand 97 
following CMV reactivation and remain stable over time whilst there is no detectable CMV 98 
viremia [12,14]. Most CMV-induced NKG2C+ NK cells express CD57, a marker of mature 99 
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and functionally differentiated NK-cells. NKG2ChiCD57hi NK cells have increased effector 100 
function and can lyse CMV-infected macrophages in the presence of CMV-specific 101 
antibodies via an ADCC mechanism [12,15]. In the presence of CMV-reactive antibodies, 102 
FcRγ-deficient (FcRγ-) NK cells from CMV-seropositive healthy donors display higher 103 
ADCC responses against CMV-infected targets than conventional NK cells. These NK cells 104 
lack the FcRγ signaling adaptor molecule, one of two adaptor chains (the other being CD3ζ) 105 
known to associate with the transmembrane domain of CD16 [16]. Thus CMV alters NK cell 106 
surface receptors and intracellular signaling adaptor molecules.  107 
 108 
In the present study, we define the effects of CMV on NK-cell surface receptors, FcRγ and 109 
NK cell function in RTR stable more than two years after transplantation with no symptoms 110 
of active CMV infection. Using a sensitive PCR, we detect subclinical CMV reactivations in 111 





CMV antibody levels are higher in RTRs than in healthy controls 117 
RTRs with a median (range) age of 54 (27 – 71) years (15 females, 33 males) were recruited 118 
8 (2-18) years after transplantation. All patients were free from clinical CMV disease or 119 
reactivation within 6 months of blood collection and receiving no current anti-viral treatment. 120 
All patients were stable on maintenance immunosuppressive therapy (Tacrolimus (n=28), 121 
Sirolimus (n=12), Cyclosporin (n=8)]. The drug regimen was not associated with CMV status 122 
(2, p=0.26). Age-matched healthy controls (13 females, 19 males) were studied in parallel.  123 
 124 
To understand the effect of CMV on NK-cell receptor repertoires and function, patients and 125 
controls were stratified by the presence of CMV antibody and CMV DNA in plasma. 126 
Antibodies were detected using CMV lysate, CMV gB and CMV IE-1 preparations (Figure 127 
1).  Eight RTR (17%) were classified as CMV seronegative (CMV Ab–). The 40 CMV 128 
seropositive RTR were further subdivided into 33 RTR (82%) without measurable CMV 129 
DNA (CMV Ab+) and 7 RTR (18%) with measurable CMV DNA (CMV Ab+DNA+; 22–2717 130 
CMV copies/ml). Of the 32 controls, 12 were CMV Ab– (38%). A representative sample of 131 
control plasmas were screened for CMV DNA and all were negative, as expected.  132 
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CMV Ab+ RTR had higher levels of IgG reactive with all three CMV antigens compared to 133 
CMV Ab+ controls (p<0.05 to <0.0001). CMV Ab+DNA+ RTR had slightly higher levels of 134 
antibody recognizing gB antigen than those without detectable viremia (p=0.03), but the 135 
presence of CMV DNA did not alter humoral responses to CMV lysate or IE-1 antigen 136 
(Figures 1A-C).  137 
 138 
CMV infection alters the phenotype of CD3¯CD56 dim NK cells in RTRs 139 
CMV may alter NK-cell receptor expression [7,17]. We compared the effect of persistent 140 
(Ab+) and active (Ab+DNA+) CMV infection in RTR and healthy controls. The proportions of 141 
CD3¯CD56bright NK cells were similar in all groups (data not shown; p=0.08-0.75), but 142 
proportions of CD3¯CD56dim NK cells were lower in CMV Ab+DNA+ RTR (p=0.01) and 143 
CMV Ab+ RTR (p=0.004) than CMV Ab¯ RTR. Frequencies were similar in CMV Ab¯ and 144 
CMV Ab+ controls (Figure 2A).  Accordingly, proportions of CD3¯CD56dim NK cells were 145 
inversely related to levels of antibody reactive with CMV gB or lysate in RTR (r = -0.35, -146 
0.36; p=0.01, 0.01, resp). The relationship was marginal in controls (r = -0.23, -0.30; p=0.20, 147 
0.10, resp.). 148 
 149 
As proportions of CD56dim NK cells were affected by CMV in RTRs, we restricted our 150 
analysis to this subset. Consistent with earlier studies [7,8,14], persistent and/or active CMV 151 
in RTRs affected expression of NKG2C, LIR-1, NKp30 and NKp46 (Figures 2B-E) on 152 
CD56dim NK cells (for gating strategy please refer to the supplementary figure). Expression 153 
of NKG2C was higher in CMV Ab+ RTR (p<0.0001) and CMV Ab+DNA+ RTR (p=0.002) 154 
than CMV Ab¯ RTR. The median (range) frequency was marginally greater (p=0.09) in CMV 155 
Ab+DNA+ RTR [20 (3 – 60) %] than CMV Ab+ RTR [5 (0.72 – 38) %]. Moreover, NKG2C 156 
expression was higher in CMV Ab+ controls (p=0.0004) than CMV Ab¯ controls (Figure 2B). 157 
To investigate variability in NKG2C expression observed in CMV-positive RTRs, all 158 
participants were genotyped for a deletion known to abrogate expression of NKG2C [18–20]. 159 
As expected, heterozygous carriers (+/-) displayed lower expression of NKG2C. Induction of 160 
NKG2C expression by CMV was clearest in CMV-seropositive patients without the deletion 161 
(+/+) (Figure 3). 162 
 163 
When LIR-1 expression was assessed as median fluorescence intensity (MFI), levels were 164 
higher in CMV Ab+DNA+ RTR than CMV Ab+ RTR (p=0.007) or CMV Ab¯ RTR (p=0.005), 165 
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showing an effect of active CMV. CMV Ab+ RTR had higher LIR-1 expression than CMV 166 
Ab+ controls (p=0.001), but CMV Ab+ and Ab¯ controls were similar (Figure 2C).   167 
 168 
Expression of NKp46 and NKp30 was lower in CMV Ab+DNA+ RTR than CMV Ab¯ RTR 169 
(p<0.05). CMV Ab+DNA+ RTR also had lower expression of NKp46 compared to CMV Ab+ 170 
RTR (p=0.03) showing an effect of active CMV. Moreover, compared to CMV Ab+ controls, 171 
CMV Ab+ RTR had decreased expression of NKp46 (p=0.0007). Expression of NKp30 was 172 
lower in CMV Ab+ controls (p=0.04) than CMV Ab¯ controls, but NKp46 expression was not 173 
affected by CMV in controls (Figure 2D-E).  174 
 175 
Expression of NKG2A, perforin, CD57, KLRG1, CD16, NKG2D and CD62L was also 176 
assessed. CMV Ab+ RTR had slightly less NKG2A+ cells compared to CMV Ab¯ RTR 177 
(p=0.05) (Figure 2F).  Perforin expression was higher in CMV Ab¯ RTR than CMV Ab¯ 178 
controls (Figure 2G), whilst expression of KLRG1 (Figure 2I) was slightly lower, suggesting 179 
an effect of transplantation or immunosuppressive drugs. Whereas CD57, CD16, NKG2D 180 
and CD62L did not exhibit any differences between groups (Figures 2H, 2J, 2K, 2L).  181 
 182 
We also assessed expression of KIR2DL1, KIR3DL1, KIR2DL2/DL3/DS2 and KIR2DS4 on 183 
CD56dim NK cells from individuals shown to carry the relevant genes after PCR amplification 184 
of extracted DNA (PCR data not shown). Expression of KIR2DL1, KIR3DL1 and 185 
KIR2DL2/2DL3/2DS2 were similar in RTR and controls, with and without CMV (Figures 186 
2M, 2N, 2O). Most (32/48) RTR did not express KIR2DS4 as they carried the KIR2DS4*003 187 
variant in which a 22bp deletion abrogates cell surface expression [21] or lacked the 188 
KIR2DS4 gene.  189 
 190 
Perforin secretion after stimulation is diminished in RTRs with active CMV infection 191 
Natural cytotoxicity depends upon the secretion of perforin and granzymes following contact 192 
with a potential target. Lower perforin secretion has been reported in NK cells from older 193 
adults following stimulation with K562 cells [22], but the authors did not assess CMV 194 
serostatus or reactivation. This is addressed here following stimulation of PBMC with anti-195 
CD16 or K562 cells.  196 
 197 
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Before in vitro stimulation, cells from CMV Ab+ RTR had lower expression of perforin than 198 
CMV Ab¯ RTR (p=0.01) (Figure 2G). After stimulation, perforin levels were similar in 199 
cultures from CMV Ab¯ RTR and CMV Ab+ RTR or CMV Ab¯ controls, so transplantation 200 
itself did not impair perforin secretion. However, perforin levels in the supernatant of NK 201 
cells from CMV Ab+DNA+ RTR was lower compared to CMV Ab+ RTR (anti-CD16 202 
p=0.004; K562 p=0.027) and CMV Ab¯ RTR (anti-CD16 p=0.05) so active CMV replication 203 
may suppress or exhaust perforin release. Intermittent CMV reactivation in CMV Ab+ RTR 204 
may activate NK cells as perforin secretion was higher in cultures from CMV Ab+ RTR than 205 
CMV Ab+ controls (K562 p=0.0009) (Figures 4A, 4B).   206 
 207 
 208 
CMV enhances the induction of CD107a on NK cells stimulated with anti-CD16  209 
We assessed changes in NK cell function (expression of CD107a and TNF-α) following in 210 
vitro stimulation with cytokines (IL-12 + IL-15 + IL-18), K562 cells or anti-CD16 (Figures 211 
4C-4H). Expression of CD107a and TNF-α were measured on NK cells expressing NKG2C, 212 
LIR-1, NKp30 and NKp46 as CMV affected expression of these markers (Figure 2). We 213 
included CD57+ CD56dim NK cells as CD57 is a marker of mature and functional NK cells. 214 
Expression of TNF- or CD107a on NKG2C+CD56dim NK cells was not quantitated in CMV 215 
Ab¯ subjects, as there were too few events (Figure 4E).  216 
 217 
Following cytokine stimulation, there were few differences between the five groups. 218 
However, CD107a expression by CD57+ and LIR-1+CD56dim NK cells was lower in CMV 219 
Ab+DNA+ RTR than CMV Ab¯ RTR (p=0.02) (Figures 4D and 4F) and CD107a expression 220 
by NKG2C+ CD56dim NK cells was higher in CMV Ab+ RTR than CMV Ab+ controls 221 
(p=0.01) (Figure 4E).  222 
 223 
Following K562 stimulation, CMV seropositivity or DNA in RTR did not alter NK cell 224 
function, but NKG2C+CD56dim NK cells had higher expression of CD107a in CMV Ab+ RTR 225 
than CMV Ab+ controls (p=0.03; Figure 4E). Compared to CMV Ab¯ controls, CMV Ab+ 226 
controls had higher expression of CD107a on CD56dim (p=0.03; Figure 4C), CD57+CD56dim 227 
(p=0.03; Figure 4D) and NKp46+CD56dim NK cells (p=0.03; Figure 4H). No significant 228 
differences were observed with TNF-α responses (data not shown; p=0.07-0.99). 229 
 230 
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After anti-CD16 stimulation, expression of CD107a on CD56dim, CD57+, LIR-1+ and NKp46+ 231 
NK cells from CMV Ab+ RTR (p<0.05) and CMV Ab+DNA+ RTR (p<0.05) was higher, 232 
compared to CMV Ab¯ RTR (Figure 4C-H). NKG2C+CD56dim NK cells had higher 233 
expression of CD107a in CMV Ab+ RTR than CMV Ab+ controls (p=0.004; Figure 4E). 234 
TNF- production was higher on CD57+, LIR-1+ and NKp46+ NK cells from CMV Ab+ RTR 235 
(p≤0.05) than CMV Ab¯ RTR (data not shown). These differences were not evident among 236 
controls. Thus persistent CMV in RTR enhances NK-mediated ADCC responses.   237 
 238 
Loss of FcRγ is a feature of LIR-1+ NK cells from CMV-seropositive individuals  239 
FcRγ-deficient cells are reported to respond robustly to anti-CD16 stimulation and CMV 240 
seropositivity increases the percentage of FcRγ– NK cells in healthy controls [16]. 241 
Accordingly, CMV Ab+ controls and CMV Ab+ RTR had higher proportions of FcRγ– NK 242 
cells than CMV Ab– controls (p<0.0001) and CMV Ab– RTR (p<0.0001), respectively. CMV 243 
Ab+DNA+ RTR had slightly higher proportions of FcRγ– NK cells than CMV Ab+ RTR 244 
(p=0.08) and significantly higher than CMV Ab– RTR (p<0.0001). Interestingly, CMV Ab+ 245 
RTR had higher proportions of FcRγ– NK cells than CMV Ab+ controls (p=0.04; Figure 5A).  246 
 247 
We then assessed expression of LIR-1 and NKG2C on FcRγ– NK cells (Figure 5B). CMV 248 
Ab+ RTR, CMV Ab+DNA+ RTR and CMV Ab+ controls had more FcRγ–LIR-1+NKG2C+ NK 249 
cells than CMV Ab– RTR (p<0.0001) or CMV Ab– controls (p=0.0007) (data not shown). 250 
Interestingly, more CD56dim NK cells had the phenotype FcRγ–LIR-1+NKG2C– than FcRγ–251 
LIR-1–NKG2C+ or FcRγ–LIR-1+NKG2C+. This was seen in CMV Ab+ RTR (p<0.05), CMV 252 
Ab+DNA+ RTR (p<0.01) and CMV Ab+ controls (p<0.01) (Figure 5C). Expansion of 253 
NKG2C–FcR– NK cells has been observed in NKG2C heterozygous carriers [23]. Here 254 
expansion of FcRγ–LIR-1+NKG2C– NK cells was found irrespective of the NKG2C 255 
genotype. When proportions of FcRγ–LIR-1+NKG2C– NK cells were assessed according to 256 
NKG2C genotype, approximately 67% of CMV Ab+DNA+ RTR (6/9), 64% of CMV Ab+ 257 
RTR (9/14) and 61% of CMV Ab+ control (11/18) were homozygous for the NKG2C gene 258 
whereas 33% of CMV Ab+DNA+ RTR (3/9), 36% of CMV Ab+ RTR (5/14) and 39% of 259 
CMV Ab+ control (7/19) were heterozygotes (NKG2C+/-). Proportions of FcRγ–LIR-260 
1+NKG2C– NK cells were then compared between NKG2C homozygous and heterozygous 261 
carriers. Among CMV Ab+ RTR, higher proportions of these cells (p=0.01) were observed in 262 
NKG2C homozygous carriers [9.5 (0.7 – 38)] than NKG2C heterozygous carriers [2.4 (0.9 – 263 
 9 
36)]. Among controls, the median (range) in NKG2C homozygous carriers was higher [3.8 264 
(1.1 – 31)] than NKG2C heterozygous carriers [1.7(0.2 – 28)], with no significant difference 265 
between the two.  266 
 267 
In comparison to CMV-positive RTR, higher expression of NKG2C on FcRγ–LIR-1+ NK 268 
cells was not observed in CMV Ab+ controls suggesting intermittent CMV reactivation may 269 
be required to up-regulate and/or maintain NKG2C on FcRγ–LIR-1+ NK cells 270 
 271 
FcRγ–LIR-1+ NK cells from CMV+ RTR display the highest ADCC responses 272 
FcRγ– NK cells show increased production of IFN-γ and expression of CD107a following 273 
stimulation designed to elicit ADCC [16]. Here we induced ADCC (induction of CD107a and 274 
TNF- by cross-linking receptors on NK cell from RTR and healthy controls with CMV gB-275 
specific antibody bound to immobilised antigen. Purified anti-CD16 was used as a positive 276 
control. Plasma from CMV-seronegative controls did not activate NK cells in PBMC 277 
preparations or purified cultured NK cells (data not shown).  278 
FcRγ–LIR-1+NKG2C– NK cells from CMV-positive RTR and controls had higher ADCC 279 
responses than FcRγ–LIR-1–NKG2C+ (p<0.05) NK cells when cross-linked with anti-CMV 280 
gB antibody (Figure 6A) or with anti-CD16 (Figure 6B). FcRγ–LIR-1+NKG2C– also had 281 
higher responses than FcRγ–LIR-1–NKG2C+ following K562 stimulation (data not shown; 282 
p=0.003 to 0.008). Thus FcRγ–LIR-1+NKG2C– NK cells exhibit higher ADCC and NK cell 283 
cytotoxicity.  284 
  285 
ADCC responses of cells defined by FcRγ–, LIR-1 and NKG2C were similar in CMV Ab+ 286 
RTR and CMV Ab+DNA+ RTR after cross-linking with patient plasma or anti-CD16 (Figures 287 





We have shown that active and latent CMV infections alter NK cell profiles in RTR who 293 
have been clinically stable for more than two years after transplantation. Specifically; CMV 294 
influenced expression of NKG2C, LIR-1, NKp30, NKp46 and FcRγ. NK cell function was 295 
assessed by induction of TNF- and CD107a. Most functional NK cells had the phenotype 296 
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FcRγ–LIR-1+ NKG2C– and displayed high ADCC responses in the presence of anti-CMV gB 297 
antibody.  298 
 299 
To understand the effect of CMV, RTR and controls were stratified based on their CMV 300 
serostatus and/or the presence of CMV DNA. A higher frequency of CMV reactivation in 301 
RTR may plausibly explain their higher levels of CMV-reactive antibody. Interestingly, 302 
CMV Ab+DNA+ RTR had particularly higher levels of antibody reactive with gB antigen. 303 
CMV gB is present on the viral envelope or exists on the surface of an infected cell and is 304 
crucial for entry into the cell [24,25]. In sera from CMV-seropositive individuals, up to 70% 305 
of neutralizing antibodies can be gB-specific [26,27]. Thus CMV Ab+DNA+ RTR may have 306 
higher gB neutralization antibody titres to control CMV replication. However, in an in-vitro 307 
study, little role for gB was found in viral neutralisation [28] so anti-gB antibody in CMV 308 
Ab+DNA+ RTR may be involved in activation of the complement pathway or cross-linking of 309 
FcγRIII (CD16) receptor on NK cells.  Alternatively, high levels may simply reflect higher 310 
antigen burdens. Unlike gB antibody, IE-1 antibody levels were not higher in CMV 311 
Ab+DNA+ RTR compared to other groups. This may arise because CMV-seronegative RTR 312 
and controls had antibody able to bind bacterial contaminants of the IE-1 preparation. 313 
 314 
 The suggestion that CMV infection may imprint on the NK cell receptor repertoire is not 315 
new [7, 29]. Similar to other studies [12-14], we show that CMV induced expression of 316 
NKG2C on CD56dim NK cells in RTR and controls. However, no greater expansion was 317 
observed in CMV Ab+DNA+ RTR than CMV Ab+ RTR. This differs from an earlier study of 318 
solid organ transplant patients [12], but the time of sample collection relative to a burst of 319 
CMV replication may be critical. Also few RTR had detectable CMV DNA, limiting the 320 
number of patients in this group. However, the patient with the highest levels of CMV DNA 321 
had abundant NKG2C+ NK cells (data not shown).  322 
 323 
CMV infection can also increase the expression of LIR-1 on NK cells from CMV-324 
seropositive healthy controls [7]. LIR-1 (CD85j/ILT2) is an inhibitory NK cell receptor that 325 
binds to classical (HLA-A, B and C) and non-classical MHC (HLA-G) class-I molecules 326 
[30]. We found the expression of LIR-1 on CD56dim NK cells was high in CMV Ab+DNA+ 327 
and CMV Ab+ RTR. In a cohort of lung transplant patients, CMV disease was associated with 328 
increased expression of LIR-1 that occurred even before viral DNA became detectable [31]. 329 
Thus, high LIR-1 expression in our cohort may reflect intermittent CMV reactivation and 330 
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mark patients at higher risk for progression to clinical disease. LIR-1 is known for its affinity 331 
to UL18, a CMV evasive protein [9,32], so up-regulation of UL18 during intermittent CMV 332 
reactivation may induce LIR-1 expression. CMV immune-evasion proteins can also suppress 333 
the expansion of cytotoxic CD56dim NK cells, so persistent and active CMV infections were 334 
associated with lower proportions of CD56dim NK cells in our cohort. 335 
 336 
CMV infection increases degranulation and IFN- production by mature NK cells [15]. NK 337 
cell cytotoxicity is mediated through the release of perforin and granzymes [33]. No previous 338 
studies have assessed how CMV affects perforin secretion after NK cell activation. Here 339 
perforin was assessed in culture supernatants following anti-CD16 and K562 stimulation. 340 
RTR with CMV DNA generated lower levels of perforin in culture, suggesting active CMV 341 
replication may impair perforin release. This needs further investigation by assessing perforin 342 
levels at the immunological synapse and binding of perforin to the target cell membrane [22]. 343 
As the CMV viral load increases in healthy individuals above 70 years of age [34], it is 344 
interesting that NK cells from older adults also displayed low perforin levels following K562 345 
stimulation [22]. Whilst Hazeldine et al [22] did not assess CMV DNA, CMV reactivation in 346 
elderly donors may impair polarization of lytic granules to the immunological synapse. 347 
Intermittent CMV reactivation and effective control of the virus in CMV Ab+ RTR may also 348 
explain why their levels of intracellular perforin were higher than CMV Ab+ controls or CMV 349 
Ab+DNA+ RTR.  350 
  351 
We also assessed expression of CD107a (also known as lysosome-associated membrane 352 
protein; LAMP-1) and TNF- after stimulating NK cells with cytokines (IL-12 + IL-15 + IL-353 
18), K562 target cells or anti-CD16. CD57 is a marker of T cell replicative senescence 354 
whereas on NK cells it is regarded as a marker of maturation. CD57+ NK cells proliferate less 355 
and produce less IFN- in response to cytokines but have higher cytotoxic capability and the 356 
ability to produce abundant cytokines when activated by a potential target cell [35]. Unlike 357 
other studies [12,36], we found no increase in CD57 expression with CMV. After cytokine 358 
stimulation, expression of CD107a on CD57+ CD56dim cells was lower in CMV Ab+DNA+ 359 
RTR. This may reflect lower expression of IL-12 and IL-18 receptors on CD57+ NK cells 360 
[35,37].  361 
 362 
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Expression of CD107a on NK cells stimulated with anti-CD16 was high in RTR with active 363 
or persistent CMV. CD56dim, CD57+, LIR-1+ and NKp46+ NK cells exhibited higher CD107a 364 
expression in CMV Ab+DNA+ RTR. This is a paradoxical finding in view of the low levels of 365 
perforin in supernatants. CD107a (LAMP-1) binds adaptor-protein 1 (AP-1) sorting complex, 366 
which is essential for perforin trafficking to lytic granules. Decreased levels of LAMP-1 or 367 
defects in AP-1 can impair perforin secretion [38]. Increased expression of CD107a and 368 
decreased perforin in the supernatants from CMV Ab+DNA+ RTR implies a defect in AP-1. 369 
This warrants further investigation.  370 
 371 
Another plausible explanation for higher expression of CD107a after anti-CD16 stimulation 372 
can be a loss of FcRCMV seropositivity correlated with loss of FcR a signaling adaptor 373 
molecule that associates with the transmembrane domain of CD16. This loss increases NK 374 
cell-mediated ADCC [16]. The decrease in FcR expression seen in RTR could explain their 375 
higher expression of CD107a after anti-CD16 stimulation. In haematopoietic cell transplant 376 
recipients, CMV reactivation caused significant loss of FcRγ expression at 6 months and 1-377 
year post-transplant [39]. Accordingly, CMV Ab+DNA+ RTR had slightly more FcRγ- NK 378 
cells (p=0.08) than CMV Ab+ RTR. An increase in FcRγ– NK cells in CMV Ab+ RTR 379 
compared with CMV Ab+ healthy controls may simply reflect intermittent episodes of CMV 380 
reactivation, driven by immunosuppressive drugs, inflammation or donor and recipient CMV 381 
serostatus at the time of transplantation. 382 
 383 
In CMV-positive people, the FcRγ– phenotype aligns with expression of NKG2C and 384 
decreased expression of NKp30 [36], which was confirmed here in both the RTR and 385 
controls. As in other studies, only a subset of FcRγ– NK cells expressed NKG2C. We noted 386 
similar frequencies of LIR-1+ and FcRγ– NK cells in a patient with the highest levels of CMV 387 
DNA (data not shown) and observed increased expression of LIR-1 and NKG2C on FcRγ– 388 
NK cells. Interestingly, FcRγ–LIR-1+NKG2C– NK cells were observed in CMV-positive RTR 389 
and controls. Expansion of FcRγ–NKG2C– NK cells is observed in NKG2C heterozygous 390 
people [23]. However in our study, expansion of FcRγ–LIR-1+NKG2C– NK cells was 391 
independent of the NKG2C genotype  so it may reflect CMV reactivation. It is unclear why 392 
NK cells downregulate FcRγ in relation to CMV infection. Following CMV infection, NK 393 
cells undergo profound epigenetic changes resulting in the downregulation of several proteins 394 
including signaling adaptor proteins (eg. FcRγ) and transcription factors (eg. PLZF – 395 
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promyelocytic leukemia zinc finger) and in turn epigenetically resemble CD8+ T cells [39]. 396 
The resultant cells are termed adaptive NK cells. The underlying mechanisms remain unclear. 397 
LIR-1 binds with high affinity to the CMV protein UL18 [9]. This interaction may trigger 398 
epigenetic changes so higher proportions of FcRγ– LIR-1+NKG2C– NK cells are observed in 399 
CMV-positive people. Further studies are required to understand the stages of differentiation.  400 
 401 
FcRγ– NK cells display increased ADCC responses in the presence of CMV-specific 402 
antibodies [16, 39]. Similarly, we observed higher CD107a and TNF-expression in FcRγ–403 
LIR-1+NKG2C– and in FcRγ–LIR-1+NKG2C+ NK cells (Figure 6). Increased polyfunctional 404 
responses in FcRγ–LIR-1+NKG2C– NK cells were also induced by K562 target cells (data not 405 
shown). Thus CMV driven FcRγ–LIR-1+NKG2C– NK cells have enhanced ADCC and NK 406 
cell cytotoxicity. However, whether FcRγ–LIR-1+NKG2C– NK cells can induce higher NK 407 
cell cytotoxicity in the presence of CMV-infected cells requires investigation. 408 
 409 
Adaptive NK cells have memory-like properties [16]. Expansion of NKG2C+ NK cells was 410 
observed in CMV seropositive but not seronegative bone marrow transplant recipients given 411 
NKG2C+ NK cells from a CMV-seropositive donor [40]. Here some CMV Ab+DNA+ RTR 412 
had high proportions of FcRγ–LIR-1+NKG2C+ NK cells and raised strong ADCC responses 413 
but this was variable. Many patients with high ADCC responses may have active CMV 414 
replication so active CMV may be essential to expand the adaptive NK cells which may in 415 
turn contribute to the control of CMV. Longitudinal studies should address whether these 416 
cells are a stable feature of some RTR or are a response to protracted CMV replication.  417 
 418 
Immunosuppressive drugs or other clinical variables such as age at transplant, CMV 419 
serostatus of donor and the recipient before transplantation may have altered the NK cell 420 
receptors in RTR however, due to small sample size and lack of clinical data the effect of 421 
these variables on NK cell receptor expression could not be determined. In spite of these 422 
limitations, our findings align with the other studies [16, 39] that demonstrate that the loss of 423 
FcRγ and increase in the expression of LIR-1 or NKG2C is associated with CMV 424 
seropositivity. Expansion of FcRγ–LIR-1+NKG2C+ and FcRγ–LIR-1+NKG2C– NK cells 425 
should be confirmed in future in a larger cohort of CMV Ab+DNA+ RTR.  426 
 427 
The changes to NK cell phenotypes associated here with CMV seropositivity (which carries a 428 
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likelihood of intermittent reactivation) are likely to be clinically important because CMV 429 
may promote vascular disease directly via infection of the endothelium [41] or indirectly by 430 
stimulating immune responses and inflammation [42]. In response to CMV infection, the 431 
recruitment of NK or T cells for its control may induce endothelial injury and promote 432 
atherogenesis. CMV-stimulated production of IFN-γ and TNF-α by CD4 T cells can induce 433 
the chemokine fractalkine, which can activate NK cells to cause endothelial damage [43]. 434 
Moreover, NK cells can destroy endothelial cells following activation by xenoantigen-435 
specific antibodies [44]. Adaptive NK cells induced by CMV may play a role in the 436 
pathogenesis of vascular disease as these cells are resistant to apoptosis during inflammatory 437 
conditions, have high proliferation rates upon engagement of an activating receptor and are 438 
highly responsive after cross-linking with CMV-specific antibodies [39]. Therefore, in an 439 
attempt to control CMV infection, enhanced activation may drive NK cells to damage 440 
endothelial cells and cause vascular disease. High CMV antibody levels in healthy 441 
individuals are linked with ischemic heart disease and expansion of NKG2C+ NK cells is 442 
associated with carotid atherosclerotic plaques in CMV seropositive patients [45,46]. Thus 443 
expression of LIR-1 and/or loss of FcRγ could be used as a biomarker to assess the risk of 444 
developing vascular disease. In summary, we demonstrate that CMV infection affects NK 445 
cell receptor expression and expands FcRγ–LIR-1+ NK cells by reactivating intermittently in 446 




MATERIALS AND METHODS 450 
Patients and Controls 451 
Renal transplant recipients were recruited from Royal Perth Hospital (RPH), Western 452 
Australia. All patients were clinically stable, free from clinical CMV disease or reactivation 453 
within 6 months of blood collection and receiving no current anti-viral treatment. All patients 454 
were on stable maintenance immunosuppressive therapy.  Age-matched healthy controls were 455 
recruited from laboratory staff and colleagues. All participants provided written informed 456 
consent and the project was approved by the Human Research Ethics Committees of RPH, 457 
the University of Western Australia and Curtin University. PBMC were isolated from 458 
heparin-treated blood using Ficoll–Paque (GE Healthcare, Little Chalfont, UK) density 459 
gradient centrifugation and cryopreserved in liquid nitrogen. Plasma samples were aliquoted 460 
and stored at -800C. 461 
 462 
Detection of CMV DNA and antibody 463 
Plasma from RTR was screened for CMV DNA in the Department of Microbiology (RPH) 464 
using commercial kits (Abbott Diagnostics, IL) able to quantitate >20 copies/ml. This value 465 
was used as a cut-off. 466 
CMV-reactive IgG was quantitated by ELISA using a lysate of human foreskin fibroblasts 467 
(HFF) infected with AD169. Cells were harvested after 7 days, sonicated and stored at -800C. 468 
Uninfected HFF were prepared as a negative control. Parallel microtitre plates were coated 469 
with CMV glycoprotein prepared in hamster ovary cells (Chiron, CA) and CMV immediate-470 
early 1 (IE-1) prepared in E.coli (Miltenyi Biotec, Germany) at 0.5µg/ml. Plates were coated 471 
overnight (40C), washed with PBS/0.05% Tween, blocked with 5%BSA/PBS and washed. 472 
Plasma samples pre-diluted in 2%BSA/PBS were run alongside control plasma from a CMV-473 
seropositive healthy individual assigned a value of 100 arbitrary units (AU). Plates were 474 
washed after 2 hours and horse-radish peroxide conjugated anti-human IgG (Sigma-Aldrich, 475 
MO) diluted 1:4000 in 2%BSA/PBS was added. Tetramethylbenzidine substrate (Sigma-476 
Aldrich) was added, colour development was stopped with 1M H2SO4 and plates were read at 477 
450nm. CMV seropositivity was defined as >2 standard deviations above the mean antibody 478 
levels derived for a set of 11 samples which had been deemed seronegative by the 479 




Cryopreserved PBMC were thawed, washed and aliquots of 106 cells were stained for 15 483 
minutes in the dark at room temperature (RT) with antibodies recognizing cell surface 484 
antigens: V500-anti-CD3 (UCHT1), V450-anti-CD56 (B159), APC-H7-anti-CD16 (3G8), 485 
APC-anti-CD57 (NK-1), PE-anti-NKp46 (9E2/NKp46), PE-anti-NKp30 (p30-15), PE-Cy7-486 
anti-NKG2D (1D11; BD Biosciences, NJ), PerCPCy5.5-anti-CD85j (HP-F1; eBioscience, 487 
CA), Alexa Fluor 488 anti-NKG2C (134591), PE-anti-KIR2DL1 (143211; R&D systems, 488 
MN), PE-anti-KIR2DL2/L3/DS2 (GL183; Beckman Coulter, CA), PerCPCy5.5-anti-CD62L 489 
(DREG-56), PE-KIR3DL1 (DX9; Biolegend, CA), PerCPCy5.5-anti-KIR2DL1/S1 (HP-490 
MA4; eBioscience). For intracellular markers, cells were incubated for 20 minutes at 40C 491 
with Cytofix/Cytoperm solution after surface staining and washed twice with cold 1X perm 492 
wash buffer (BD Cytofix/Cytoperm kit). Cells were then stained with 5µL PerCPCy5.5-anti-493 
perforin (DG9; Biolegend) for 30 minutes in the dark at RT. After incubation, cells were 494 
washed twice with cold 1X perm wash buffer. At least 100,000 events were acquired in the 495 
lymphocyte gate on a FACSCanto II instrument (BD Biosciences). Data were analysed with 496 
FlowJo v10 software (Tree Star, OR). 497 
 498 
Perforin ELISA 499 
PBMCs were stimulated with anti-CD16 or K562 cells for 6 hours and supernatants were 500 
collected after 6 hours and stored at -800C. Perforin levels were measured using a commercial 501 
human Perforin ELISA kit (Abcam, Cambridge, UK) able to detect <40 pg/mL. 502 
 503 
Functional Assays 504 
Cryopreserved PBMC were thawed, washed and stimulated (0.5 x 106 cells/100 µL) with 505 
cytokines [IL-12 (10ng/mL; R & D systems) + IL-15 (10ng/mL; R & D systems) + IL-18 (10 506 
ng/mL; MBL, Japan)] for ~ 16 hours at 370C and 5% CO2. Remaining PBMC were rested 507 
overnight and next day these cells (5x105/100 µL) were stimulated for 6 hours at 37°C with 508 
RPMI 1640/10% FBS, 10µg anti-CD16 (BD Biosciences) bound to flat-bottomed 96-well 509 
plates or K562 cells at an effector-to-target ratio of 2:1. BV786-anti-CD107a (H4A3; BD 510 
Biosciences) was added to all wells. After 1 hour, brefeldin A and monensin (BD 511 
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Biosciences) were added and cells were incubated for a further 5 hours at 37°C. Cells were 512 
then stained with a live/dead dye; FVS700 (BD Biosciences) for 30 minutes, followed by 513 
BUV395-anti-CD3 (UCHT1), BV510-anti-NKp46 (9E2/NKp46), PE-CF594-anti-CD57 514 
(NK-1), BV421-anti-NKp30 (p30-15; BD Biosciences), PE.Cy7-anti-CD56 (HCD56; 515 
Biolegend), APC-anti-NKG2C (134591; R&D systems) and PE-anti-LIR-1 (HP-F1; 516 
eBioscience) for 15 minutes in the dark at RT. Cells were then fixed for 20 minutes at 40C, 517 
permeabilized (BD Cytofix/Cytoperm™; BD Biosciences), stained for intracellular antigens 518 
using BV650-anti-TNF- (MAb11; Biolegend) and FITC-anti-FceRI (Merck Millipore, 519 
Germany) for 30 minutes and was washed twice with cold 1X perm wash buffer. At least 520 
100,000 events were acquired in the lymphocyte gate on a BD LSR II Fortessa Instrument 521 
(BD Biosciences). Data were analysed with FlowJo v10 software (Tree Star, OR). 522 
 523 
ADCC Assay 524 
96-well plates were coated with CMV gB antigen at 0.5µg/ml and incubated overnight at 525 
40C. Wells were washed and blocked for 60 minutes at RT with 10% FBS/RPMI. 100µL 526 
aliquots of heat-inactivated (56°C, 1 hour) autologous plasma were added to the coated wells, 527 
incubated overnight at 40C. The optimal dilution (1:300) was selected in preliminary 528 
experiments that displayed highest expression of CD107a and production of TNF-. Wells 529 
were washed and 5x105 PBMCs were added with BV786-anti-CD107a (H4A3; BD 530 
Biosciences) for 1 hour followed by brefeldin A and monensin (BD Biosciences) for a further 531 
5 hours at 37°C. Cells were stained as described under the functional assay.  532 
 533 
Genotyping  534 
A deletion mutation abrogating expression of NKG2C was assessed by a nested PCR-based 535 
method with two primer pair sequences [18] to distinguish homozygosity and heterozygosity.  536 
 537 
Statistical analyses 538 
Statistical analyses were performed using Prism 5 (GraphPad Software, CA). Nonparametric 539 
tests were conducted to determine statistical significances. Mann–Whitney tests were used to 540 
compare results between groups. Wilcoxon matched pairs tests were used to compare results 541 
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within a patient or control group. Correlation coefficients were calculated with Spearman’s 542 
tests. All p values ≤0.05 were considered to be statistically significant. 543 
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FIGURE LEGENDS 705 
 706 
FIGURE 1.  Antibody responses to CMV antigens. (A-C) Plasma from healthy controls 707 
and RTRs was collected to assess CMV-reactive IgG levels. IgG levels were assessed against 708 
(A) CMV lysate antigen, (B) gB antigen and (C) IE antigen using ELISA in CMV Ab‒ RTR 709 
(n=8), CMV Ab+ RTR (n=33), CMV Ab+DNA+ RTR (n=7), CMV Ab‒ control (n=12) and 710 
CMV Ab+ controls (n=20). Data are shown as means derived from three-fold serial dilutions 711 
of duplicate wells and are representative of one independent experiment. Groups were 712 
compared using Mann-Whitney tests. The boxes represent the 25th and 75th percentiles and 713 
the central line represents the median. The end of the whiskers represents the minimum and 714 




FIGURE 2. NK-cell phenotypes in association to CMV antibody and/or CMV DNA or 719 
transplantation. Multiparametric flow cytometry analysis were performed using 720 
cryopreserved PBMCs from CMV Ab‒ RTR (n=8), CMV Ab+ RTR (n=33), CMV Ab+DNA+ 721 
RTR (n=7), CMV Ab‒ control (n=12) and CMV Ab+ controls (n=20) to assess the expression 722 
of NK cell receptors. One independent experiment is shown here. Two subsets of NK cells 723 
were identified using anti-CD3 and anti-CD56: CD3–CD56bright and CD3–CD56dim. Analyses 724 
were restricted to CD3–CD56dim NK cells. (A) Proportions of CD3–CD56dim NK cells. (B) 725 
Expression of NKG2C on CD56dim NK cells. (C) MFI of LIR-1 on CD56dim NK cells. (D) 726 
Expression of NKp30 on CD56dim NK cells. (E) Expression of NKp46 on CD56dim NK cells. 727 
 24 
(F) Expression of NKG2A on CD56dim NK cells. (G) Expression of perforin on CD56dim NK 728 
cells. (H) Expression of CD57 on CD56dim NK cells. (I) Expression of KLRG1 on CD56dim 729 
NK cells. (J) Expression of CD16 on CD56dim NK cells. (K) Expression of NKG2D on 730 
CD56dim NK cells. (L) Expression of CD62L n CD56dim NK cells. (M) Expression of 731 
KIR2DL1 on CD56dim NK cells. (N) Expression of KIR3DL1 and (O) Expression of 732 
KIR2DL2/DL3/DS2 on CD56dim NK cells. Groups were compared using Mann-Whitney 733 
tests. The boxes represent the 25th and 75th percentiles and the central line in represents the 734 
median. The end of the whiskers represents the minimum and maximum. Statistical 735 
significance is indicated as *p ≤ 0.05, **p<0.01, ***p< 0.001, ****p< 0.0001. 736 
 737 
 738 
FIGURE 3. Expression of NKG2C in association to CMV antibody and/or CMV DNA 739 
and NKG2C genotype.  740 
A nested PCR was performed to detect a deletion mutation that abrogates expression of 741 
NKG2C. Based on the NKG2C genotype, CMV antibody levels and DNA levels, RTRs and 742 
controls [CMV Ab‒ RTR (n=8), CMV Ab+ RTR (n=33), CMV Ab+DNA+ RTR (n=7), CMV 743 
Ab‒ control (n=12) and CMV Ab+ controls (n=20)] were further stratified to assess the 744 
expression of NKG2C. Induction of NKG2C expression on NK cells by the presence of CMV 745 
antibody was clearest in RTRs with homozygous presence of NKG2C (+/+). RTR with 746 
heterozygous (+/-) genotype had decreased expression of NKG2C than homozygotes (+/+). 747 
There were no individuals with the genotype (-/-). Each symbol represents an individual 748 
donor. One independent experiment is represented here. Groups were compared using Mann-749 
Whitney tests. Medians are represented by lines and statistical significance is indicated as 750 
**p<0.01, **** p< 0.0001.  751 
 752 
 753 
FIGURE 4. Analysis of perforin secretion and CD107a expression  754 
(A, B) Cryopreserved PBMCs from CMV Ab‒ RTR (n=6), CMV Ab+ RTR (n=17), CMV 755 
Ab+DNA+ RTR (n=7), CMV Ab‒ control (n=7) and CMV Ab+ controls (n=9) were stimulated 756 
with either (A) anti-CD16 or (B) K562 cells for 6 hours to assess perforin levels (pg/ml) in 757 
the culture supernatants by ELISA. Data are means of duplicate wells in one independent 758 
experiment. (C-H) PBMCs from CMV Ab‒ RTR (n=10), CMV Ab+ RTR (n=15), CMV 759 
Ab+DNA+ RTR (n=9), CMV Ab‒ control (n=10) and CMV Ab+ controls (n=10) were 760 
stimulated with either cytokines (IL-12 + IL-15 + IL-18), K562 target cells or anti-CD16 for 761 
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6 hours and expression of CD107a was assessed using multiparametric flow cytometry on (C) 762 
CD56dim NK cells, (D) CD57+CD56dim NK cells, (E) NKG2C+CD56dim NK cells, (F) LIR-763 
1+CD56dim NK cells, (G) NKp30+CD56dim NK cells and (H) NKp46+CD56dim NK cells. One 764 
independent experiment is represented here. Groups were compared using Mann-Whitney 765 
tests.  The boxes represent the 25th and 75th percentiles and the central line represents the 766 
median. The end of the whiskers represents the minimum and maximum. Statistical 767 
significance is indicated as *p ≤ 0.05, **p<0.01, ***p< 0.001. 768 
 769 
 770 
Figure 5. Co-expression of FcRγ–, LIR-1+ and NKG2C+ NK cells in RTRs and controls 771 
(A, B) Multiparametric flow cytometry analyses were performed on cryopreserved PBMCs 772 
from CMV Ab‒ RTR (n=10), CMV Ab+ RTR (n=14), CMV Ab+DNA+ RTR (n=9), CMV 773 
Ab‒ control (n=10) and CMV Ab+ controls (n=10) to determine the (A) percentage of 774 
CD56dim NK cells with the FcRγ- phenotype. (B) Gating strategy of co-expression of LIR-775 
1+NKG2C+ on FcRγ– CD56dim NK cells is shown. (C) Boolean gating was performed to 776 
compare different subsets of FcRγ– NK cells expressing LIR-1 and NKG2C. Each symbol 777 
represents an individual donor. One independent experiment is represented here. Groups were 778 
compared using Mann-Whitney tests. Medians are represented by lines and statistical 779 
significance is indicated as *p ≤ 0.05, **p<0.01, ****p< 0.0001. 780 
 781 
 782 
Figure 6. ADCC by different subsets of FcRγ–, LIR-1+ and NKG2C+ NK cells.                   783 
(A, B) Cryopreserved PBMCs from CMV Ab‒ RTR (n=10), CMV Ab+ RTR (n=14), CMV 784 
Ab+DNA+ RTR (n=9), CMV Ab‒ control (n=10) and CMV Ab+ controls (n=10) were 785 
stimulated for 6 hours by autologous plasma bound to immobilised CMV gB antigen or 786 
purified anti-CD16 to elicit an ADCC response (assessed by expression of CD107a and TNF-787 
). Boolean gating was performed to assess different subsets of CD56dim NK cells expressing 788 
FcRγ, LIR-1, NKG2C, CD107a and TNF- after cross-linking NK cells with either (A) 789 
autologous plasma or (B) purified anti-CD16. For both figures, CMV Ab+ controls are plotted 790 
on the right and RTR on the left Y-axis. Patient and control groups were compared using 791 
Mann-Whitney tests. NK subsets were compared within patient/control groups using 792 
Wilcoxon matched pairs tests. One independent experiment is represented here. The boxes 793 
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represents minimum to maximum, the line in the box represents the median and statistical 794 
significance is indicated as *p ≤ 0.05, **p<0.01, ***p< 0.001.  795 
 
 
 
 
  
 
 
 
 
